Profile data is unavailable for this security.
About the company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
- Revenue in USD (TTM)2.79bn
- Net income in USD655.77m
- Incorporated1998
- Employees2.64k
- LocationGenmab A/SCarl Jacobsens Vej 30VALBY 2500DenmarkDNK
- Phone+45 70202728
- Fax+45 70202729
- Websitehttps://www.genmab.com/
More ▼
Mergers & acquisitions
| Acquired company | GMAB:CPH since announced | Transaction value |
|---|---|---|
| ProfoundBio US Co | -30.61% | 1.80bn |
Data delayed at least 15 minutes, as of Nov 21 2024 15:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | 742.00k | -567.06m | 9.60bn | 490.00 | -- | 6.11 | -- | 12,938.38 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 9.61bn | 20.00k | 23.46 | 2.54 | 12.51 | 2.37 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.75bn | 6.50k | -- | 3.04 | 5,350.26 | 3.62 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 9.90bn | 1.31k | 22.08 | 4.35 | 20.01 | 4.75 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 10.14bn | 5.90k | 28.55 | 11.47 | 25.70 | 4.89 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.59bn | 1.31k | 91.16 | 8.67 | 65.98 | 6.46 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 10.71bn | 254.00 | -- | 3.13 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 10.92bn | 3.10k | 73.09 | 5.11 | 41.67 | 9.32 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.48bn | 1.70k | 33.02 | 4.59 | 30.33 | 5.57 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Insmed Inc | 342.96m | -864.29m | 13.00bn | 912.00 | -- | 26.89 | -- | 37.91 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Genmab A/S - ADR | 2.79bn | 655.77m | 13.58bn | 2.64k | 20.27 | 2.88 | 32.34 | 4.86 | 1.01 | 1.01 | 4.29 | 7.10 | 0.5277 | 10.98 | 3.37 | 1,267,565.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| Summit Therapeutics Inc | 0.00 | -196.68m | 13.73bn | 105.00 | -- | 31.34 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 14.22bn | 5.60k | -- | 1.19 | -- | 2.80 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| United Therapeutics Corporation | 2.76bn | 1.11bn | 16.27bn | 1.17k | 16.01 | 2.66 | 13.81 | 5.90 | 22.75 | 22.75 | 56.36 | 136.74 | 0.3897 | 2.43 | 9.18 | 2,359,760.00 | 15.71 | 10.38 | 17.73 | 11.27 | 88.94 | 91.47 | 40.31 | 29.25 | 4.41 | -- | 0.0615 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| ICON PLC | 8.31bn | 747.89m | 16.81bn | 42.25k | 22.64 | 1.72 | 13.04 | 2.02 | 8.99 | 8.99 | 99.87 | 118.39 | 0.4852 | -- | 2.99 | 202,112.50 | 4.37 | 3.93 | 5.24 | 4.80 | 29.65 | 28.91 | 9.00 | 7.37 | -- | 4.41 | 0.2599 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Data as of Nov 21 2024. Currency figures normalised to Genmab A/S's reporting currency: US Dollar USD
5.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AllianceBernstein LPas of 30 Sep 2024 | 15.14m | 2.29% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 4.42m | 0.67% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.13m | 0.62% |
| Harding Loevner LPas of 30 Sep 2024 | 3.07m | 0.46% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 2.29m | 0.35% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 1.79m | 0.27% |
| Orbis Investment Management Ltd.as of 30 Sep 2024 | 1.68m | 0.25% |
| First Trust Advisors LPas of 30 Sep 2024 | 1.39m | 0.21% |
| Citadel Advisors LLCas of 30 Sep 2024 | 1.27m | 0.19% |
| Envestnet Asset Management, Inc.as of 30 Sep 2024 | 1.04m | 0.16% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
